COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05614245

William Cameron

Not reported

2022-11-14

Withdrawn

RCT

Randomized

Sequential assignment

Open label

multi-center

Prevention

inclusion criteria: male or female subject 18-40 years of age be willing and able to provide personally signed informed consent indicating understanding of the purpose, procedures required for the study and potential risks and benefits of the study, and be willing to participate in the study healthy participants with no chronic medical conditions at study enrollment and during the 6 months before enrollment. participants with history of asymptomatic sars-cov-2 infection who tested positive by pcr or rapid antigen test or participants with history of having signs and symptoms mild covid-19 illness (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who did not have shortness of breath, dyspnea, or abnormal chest imaging are eligible for the study if they fully recovered a minimum of 6 months before enrollment. meets reproductive inclusion criteria female participant is eligible if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: • is of childbearing potential and must have a negative pregnancy test prior to study vaccinations and agree to use an effective method of birth control as deemed appropriate by the investigator (e.g., hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device) beginning >30 days prior to the first study vaccine administration and continuing for a minimum of 30 days after the last dose of study vaccine. or • is not of childbearing potential, defined as postmenopausal (a minimum of 12 months with no menses without an alternative medical cause) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). male participant is eligible to participate if he agrees to the following requirements from the time of first study vaccination until at least 30 days after the last dose of study vaccine: be abstinent from heterosexual intercourse with a female of childbearing potential or must agree to use a male condom. in addition to male condom use, an effective method of contraception may be considered in female partners of male participants and must refrain from sperm donation have previously received 2 or more doses of a licensed covid-19 vaccine(s) with the last dose administered a minimum of 6 months (24 weeks) prior to enrollment. participants vaccinated with any of the vaccines approved by health canada for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars- cov-2) in individuals 18 years of age and older are eligible for the study. this includes the following covid-19 vaccines: moderna spikevax®, pfizer-biontech comirnaty®, astrazeneca vaxzevria®, janssen jcovden® (johnson & johnson), novavax nuvaxovid® and medicago covifenz®. participants who received one or more doses of vbi-2902a, vbi-2905a or any other covid-19 vaccines that are either investigational or not approved by health canada are not eligible for the study.

history of covid-19 illness of moderate or greater severity, defined as one of the following: moderate illness: individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (spo2) ≥94% on room air at sea level. severe covid-19 illness: individuals who have spo2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) <300 mm hg, a respiratory rate >30 breaths/min, or lung infiltrates >50%. critical covid-19 illness: individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction. positive sars-cov-2 pcr or rapid antigen test at screening. history of sars or mers. participant with a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation in the study would not be in the best interest of the participant (e.g., could compromise participant's wellbeing) or that could prevent, limit, or confound the protocol-specified assessments. individuals with medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. history of cancer requiring chemotherapy or radiation within 5 years. lack of participant's capacity (mental, social, behavioral), in the investigator's judgement, to provide informed consent for participation in the study. known or suspected impairment of immunological function, including but not limited to: autoimmune diseases (e.g., multiple sclerosis, type 1 diabetes, myasthenia gravis, crohn's disease and other inflammatory bowel diseases, celiac disease, systemic lupus erythematosus, scleroderma, including diffuse systemic form and crest syndrome, systemic sclerosis, dermatomyositis polymyositis, rheumatoid arthritis, juvenile idiopathic arthritis, autoimmune thyroiditis - including hashimoto thyroiditis, grave's or basedow's disease, immune thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune hepatitis, psoriasis, vitiligo, vasculitis, guillain- barré syndrome, transverse myelitis, addison's disease, bell's palsy and alopecia areata) or abnormal or positive test result for any of the following tests at the study screening visit: ana (antinuclear antibody) rf (rheumatoid factor) ttg-iga (tissue transglutaminase iga antibody) crp (c-reactive protein) tgab (thyroglobulin antibody) primary immunodeficiency disorders (e.g., common variable immune deficiency (cvid), defective phagocytic cell function and neutropenia syndromes, complement deficiency). secondary immunodeficiency disorders (e.g., acquired immunodeficiency syndrome caused by human immunodeficiency virus infection (hiv/aids), solid organ transplant, splenectomy) history of allergic reactions or anaphylactic reaction to any vaccine component. known infection with human immunodeficiency virus (hiv), hepatitis c virus (hcv), or hepatitis b virus (hbv). negative result of anti-hiv, anti-hcv and hbsag testing at screening is required for eligibility. pregnant or breastfeeding or plans to conceive from 2 weeks before the study until the end of study. clinically significant abnormal physical examination, vital signs, or clinically significant abnormal values for hematology, serum chemistry or urinalysis at screening as determined by the investigator. any laboratory test abnormality that would be considered of grade 1 severity or above (as per fda grading guidelines) and is considered as clinically significant by the investigator. grade 2 severity or above is exclusionary, regardless of clinical assessment. receipt of blood products or immunoglobulin within 90 days prior to enrollment or likely to require blood products during the study period. chronic administration (defined as more than 14 days in total) of immune-suppressive or other immune-modifying drug within 6 months prior to enrollment (for corticosteroids, this is defined as prednisone ≥20 mg/day or equivalent). inhaled and topical steroids are allowed. immunization with attenuated vaccines (e.g., shingles) within 4 weeks prior to enrollment. immunization with inactivated vaccines (e.g., influenza) within 2 weeks prior to enrollment. participation in another clinical study within 30 days prior to enrollment. participants who received one or more doses of vbi-2902a or vbi-2905a or other investigational covid-19 vaccines are not eligible for the study. any skin abnormality or tattoo that would limit post-vaccination injection site assessment. family members of study site personnel.

6

VBI Vaccines Inc.

18

40

Canada

Healthy volunteers

N/A

0

Local reactions (solicited adverse events) within 7 days of study vaccination;Medically-attended adverse events within 28 days of study vaccination and end of study;Serious adverse events within 28 days of study vaccination and end of study;Seroresponse rate against SARS-CoV-2 ancestral (Wuhan) strain;Systemic reactions (solicited adverse events) within 7 days of study vaccination;Unsolicited adverse events within 28 days of study vaccination

None

Phase 1

[{"arm_notes": "5 \u00b5g with 1 \u00b5g E6020 per dose on Day 1", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g with 1 \u00b5g E6020 per dose on Day 1 and Day 28", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g with 3 \u00b5g E6020 per dose on Day 1", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g with 3 \u00b5g E6020 per dose on Day 1 and Day 28", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g with 10 \u00b5g E6020 per dose on Day 1", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g with 10 \u00b5g E6020 per dose on Day 1 and Day 28", "treatment_id": 2649, "treatment_name": "Vbi-2901e", "treatment_type": "Virus-like particle", "pharmacological_treatment": "Vaccine"}]